# Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons

> **NCT06515834** · PHASE1 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Gastroenterology

## Interventions

- **DRUG:** FE 999301
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06515834
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-01
- **Primary completion:** 2024-11-28
- **Final completion:** 2024-11-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06515834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06515834, "Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06515834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*